China's stocks rose again on Wednesday, extending their performance as one of the world's best performers after the United Kingdom's shock vote to leave the European Union, because the market's dominance by local traders helped insulate the nation's shares from global turmoil.
Visa sponsors roving educational bus
China's banking industry has improved its policy framework to support the development of an environment-friendly, circular and low-carbon economy, said a corporate social responsibility report released by the China Banking Association on Friday.
Rolls-Royce Holdings Plc, the famed global aircraft engine manufacturer, has signed an agreement with the Civil Aviation Administration of China to further expand an existing training program for senior executives in the fast-growing Chinese aviation industry.
The Asian Infrastructure Investment Bank will finance projects as per prudential norms, avoiding irrational moves, Jin Liqun, the lender's president, said on Tuesday.
Information technologies and innovation are not only reshaping the landscape of manufacturing but changing the roadmap of the virtual financial sector.
The world's top insulin producer by sales is confident that China's focus on innovation will spur it toward new partnerships with local entrepreneurs for technology solutions to complement modern treatments for diabetics, said Jakob Riis, executive vice-president of China and Pacific & marketing, Novo Nordisk A/S.
Despite China's slowing economy, Royal DSM NV, the Netherlands-based nutrition and material sciences company, said it will continue its investment in the country as affluent consumers are willing to pay more for their health.
Zhang Ruimin, chairman of Haier Group, said China's largest maker of home appliances will continue to be the platform where different cultures could coexist, thrive and contribute creative inputs for innovation in the industry, in line with the government's current emphasis.
Fantawild Holdings Inc, one of China's leading theme park brands, plans to ride the boom in the sector and double the number of its parks over the next five to ten years.
Pfizer Inc said Tuesday it will invest $350 million in Hangzhou, eastern China on a plant for biotechnology drugs, bolstering its presence in the world's second biggest pharmaceutical market despite slowing economic growth in the country and rising pressure on prices for medicines.
|
|
|
|
|
|
|
|